 |
|
Half- vs Full-Dose Trivalent Inactivated Influenza Vaccine (2004-2005)Age, Dose, and Sex Effects on Immune Responses
Renata J. M. Engler, MD;
Michael R. Nelson, MD, PhD;
Mary M. Klote, MD;
Mark J. VanRaden, PhD;
Chiung-Yu Huang, PhD;
Nancy J. Cox, PhD;
Alexander Klimov, PhD, ScD;
Wendy A. Keitel, MD;
Kristin L. Nichol, MD;
Warner W. Carr, MD;
John J. Treanor, MD; for the Walter Reed Health Care System Influenza Vaccine Consortium
Arch Intern Med. 2008;168(22):2405-2414.
Background Optimal public health strategies for managing influenza vaccine shortages are not yet defined. Our objective was to determine the effects of age, sex, and dose on the immunogenicity of intramuscular trivalent inactivated vaccine (TIV).
Methods Healthy adults aged 18 to 64 years, stratified by age (18-49 and 50-64 years) and sex, were randomized to receive full- or half-dose TIV. Hemagglutination inhibition titers against vaccine antigens were measured before and 21 days after immunization. A primary outcome of noninferiority was defined as a difference of less than 20% in the upper 95% confidence interval (CI) of the proportion of subjects with strain-specific hemagglutination inhibition antibody titers of 1:40 or higher after vaccination. Secondary outcomes included geometric mean titers, after vaccination side effects, and occurrences of influenza-like illnesses.
Results Among previously immunized subjects (N = 1114) receiving half- vs full-dose TIV (age, 18-49 years, n = 284 [half] and n = 274 [full]; and age 50-64 years, n = 276 [half] and n = 280 [full]), CIs for proportions of subjects with hemagglutination inhibition antibody titers of 1:40 or higher excluded substantial reduction for all antigens in the 18- to 49-year age group and for B/Shanghai/361/2002 (B) and A/Fujian/411/2002 (A/H3N2) in the 50- to 64-year age group. Geometric mean titer in the female 18- to 49-year age group exceeded male responses for all strains: responses to half-dose TIV that were comparable with male full-dose responses for A/New Caledonia/20/99 (A/H1N1) antigen, 25.4 (95% CI, 20.9-30.9) vs 25.6 (95% CI, 21.3-30.9); A/H3N2 antigen, 60.8 (95% CI, 50.8-72.7) vs 44.1 (95% CI, 37.6-51.8); and B antigen, 64.4 (95% CI, 53.9-76.9) vs 60.7 (95% CI, 51.4-71.7) (findings were similar for the 50- to 64-year age group). Some injection site and systemic reactions (myalgias and/or arthralgias [P < .05], headache [P < .001], and impact of fatigue [P < .05]) were significantly lower in men. The relative risk of medical visits and hospitalizations for influenza-like illnesses were similar in the half- and full-dose groups regardless of age.
Conclusions Antibody responses to intramuscular half-dose TIV in healthy, previously immunized adults were not substantially inferior to the full-dose vaccine, particularly for ages 18 to 49 years. Significantly higher geometric mean titer responses in women were identified for all ages, regardless of dose or influenza strain. Half-dose vaccination may be an effective strategy for healthy adults younger than 50 years in the setting of an influenza vaccine shortage.
Trial Registration clinicaltrials.gov Identifier: NCT00283283
Author Affiliations: Allergy-Immunology Department, Walter Reed Army Medical Center, Washington, DC (Drs Engler, Nelson, and Klote); National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland (Drs VanRaden and Huang); Influenza Branch, Centers for Disease Control and Prevention, Atlanta, Georgia (Drs Cox and Klimov); Baylor College of Medicine, Houston, Texas (Dr Keitel); VA Medical Center and Department of Medicine, University of Minnesota Medical School, Minneapolis (Dr Nichol); Allergy and Asthma Associates of Southern California, Mission Viejo (Dr Carr); and Infectious Diseases Unit, Department of Medicine, University of Rochester, Rochester, New York (Dr Treanor).
 CiteULike  Connotea  Delicious  Digg  Facebook  Reddit  Technorati  Twitter
What's this?
RELATED ARTICLES
In This Issue of Archives of Internal Medicine
Arch Intern Med. 2008;168(22):2400.
FULL TEXT
Half-Dose Influenza Vaccine: Stretching the Supply or Wasting It?
Ann R. Falsey
Arch Intern Med. 2008;168(22):2402-2403.
EXTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Immune Response Following H1N1pdm09 Vaccination: Differences in Antibody Repertoire and Avidity in Young Adults and Elderly Populations Stratified by Age and Gender
Khurana et al.
The Journal of Infectious Disease 2012;205:610-620.
ABSTRACT
| FULL TEXT
Immunogenicity of an Inactivated Monovalent 2009 H1N1 Influenza Vaccine in Pregnant Women
Jackson et al.
The Journal of Infectious Disease 2011;204:854-863.
ABSTRACT
| FULL TEXT
Randomized Controlled Trial of Dose Response to Influenza Vaccine in Children Aged 6 to 23 Months
Skowronski et al.
Pediatrics 2011;128:e276-e289.
ABSTRACT
| FULL TEXT
Efficacy of experimental treatments compared with standard treatments in non-inferiority trials: a meta-analysis of randomized controlled trials
Soonawala et al.
Int J Epidemiol 2010;39:1567-1581.
ABSTRACT
| FULL TEXT
Estrogen Receptors Bind to and Activate the HOXC4/HoxC4 Promoter to Potentiate HoxC4-mediated Activation-induced Cytosine Deaminase Induction, Immunoglobulin Class Switch DNA Recombination, and Somatic Hypermutation
Mai et al.
J. Biol. Chem. 2010;285:37797-37810.
ABSTRACT
| FULL TEXT
A Single Dose of Unadjuvanted Novel 2009 H1N1 Vaccine Is Immunogenic and Well Tolerated in Young and Elderly Adults
Talaat et al.
The Journal of Infectious Disease 2010;202:1327-1337.
ABSTRACT
| FULL TEXT
Immunogenicity and Safety of Intradermal Influenza Vaccination in Healthy Older Adults
Chi et al.
Clinical Infectious Diseases 2010;50:1331-1338.
ABSTRACT
| FULL TEXT
Half-Dose Influenza Vaccine: Stretching the Supply or Wasting It?
Falsey
Arch Intern Med 2008;168:2402-2403.
FULL TEXT
|
